M. Thomas

Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.

Y. Houvras, A. Mansfield, J. Mazières, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

E. Sokol, T. Wilson, F. D. De Braud, 2021, npj Precision Oncology.

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

H. Moch, A. Krämer, L. Mileshkin, 2021, The oncologist.

MA14.01 Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non–Small Cell Lung Cancer

A. Stenzinger, J. Hong, P. Christopoulos, 2021, Journal of Thoracic Oncology.

LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)

A. Ardizzoni, C. Bossen, F. Barlesi, 2022, Annals of Oncology.

Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer.

Jeffrey M. McManus, S. Chandarlapaty, S. Nik-Zainal, 2021, Journal of Clinical Oncology.

Post-operative opioid consumption in Thoracic Surgery Patients: How much is actually used?

D. Wigle, S. Blackmon, E. Habermann, 2020, The Annals of thoracic surgery.

OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

P. Paik, J. Mazières, Y. Wu, 2022, Journal of Thoracic Oncology.

P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy

P. Paik, E. Felip, C. Stroh, 2021, Journal of Thoracic Oncology.

8P Pre-treatment blood gene expression changes associated with durable clinical benefit in metastatic non-small cell lung cancer with high PD-L1 expression receiving first-line pembrolizumab

M. Kriegsmann, A. Stenzinger, M. Meister, 2021, Annals of Oncology.